{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_21", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-25 17:35:0", "close_timestamp": 1637861700499, "created": "25/11/2021 17:35:02", "department": "Visual Cultures", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-11-25", "gender": "female", "id": "4b7da880-0529-491e-987e-cf2f35e3522f", "open_date_time": "2021-10-25 17:28:26", "open_timestamp": 1637861306892, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "Research at Monash BDI and the Doherty Institute led by Dr Kyle Wagstaff shows that the anti-parasitic drug Ivermectin has been shown to stop the growth of SARS-CoV-2 cells within 48hours. Ivermectin is a safe and widely available drug already approved by the FDA.", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_phd", "time_taken_in_seconds": 393607, "what": "Ivermectin, SARS-CoV-2, FDA, anti-viral research", "when_happened": "few_years_ago", "where_location": "Melbourne Australia", "who": "Dr Kylie Wagstaff, Monash BDI, University of Melbourne, Royal Melbourne Hospital", "why": "Ivermectin is already approved and available"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_21", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-25 17:17:37", "close_timestamp": 1637860657608, "created": "25/11/2021 17:17:40", "department": "Visual Cultures", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-25", "gender": "female", "id": "45d8c445-eb5e-41ba-994c-f4cb86f2177d", "open_date_time": "2021-10-25 17:8:17", "open_timestamp": 1637860097387, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "The Novavax vaccine trials developed by Nasdaq in the USA are experiencing supply issues from Mexico.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_phd", "time_taken_in_seconds": 560221, "what": "COVID-19, vaccine trials, Novavax, USA", "when_happened": "current_month", "where_location": "United States", "who": "Nasdaq, USA", "why": "USA is experiencing supply problems for vaccine"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_21", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-25 17:7:19", "close_timestamp": 1637860039397, "created": "25/11/2021 17:07:21", "department": "Visual Cultures", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-25", "gender": "female", "id": "8dc8c313-a14f-47d4-8c8f-6436f047c69f", "open_date_time": "2021-10-25 16:57:47", "open_timestamp": 1637859467854, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "GPs in Australia are being urged by the government to prescribe a new 'triple therapy' for coronavirus comprising ivermectin, zinc and doxycycline for fighting and curing coronavirus and saving lives.", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_phd", "time_taken_in_seconds": 571543, "what": "ivermectin, coronavirus pandemic, vaccine, medicine, Australia", "when_happened": "few_month_ago", "where_location": "Australia", "who": "Australian GPs", "why": "a new coronavirus therapy for saving lives"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_21", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-25 17:28:17", "close_timestamp": 1637861297957, "created": "25/11/2021 17:28:19", "department": "Visual Cultures", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-25", "gender": "female", "id": "6491f7b0-80d6-4afa-913e-7e490faf7b7d", "open_date_time": "2021-10-25 17:17:49", "open_timestamp": 1637860669548, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "In December 2020 Japanese company Chugai Pharmaceutical has licensed the exclusive rights to the triple antibody drug cocktail Ronapreve to improve survival in high risk patients during the COVID-19 pandemic. Ronapreve has also been authorised for use in emergency conditions in countires in the EU, USA, India, Switzerland and Canada. ", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_phd", "time_taken_in_seconds": 628409, "what": "COVID-19, Ronapreve, Japan, ", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Roche, Regeneron, Chugai Pharmaceutical, Japan", "why": "Ronapreve reduces the risk of hospitalisation and death"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_21", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-25 17:57:29", "close_timestamp": 1637863049318, "created": "25/11/2021 17:57:31", "department": "Visual Cultures", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-25", "gender": "female", "id": "191f0cf0-3d02-488b-80f5-75d974bbb845", "open_date_time": "2021-10-25 17:50:18", "open_timestamp": 1637862618173, "summary": "A collaboration between Myovant Sciences and Pfizer have announced that the FDA has approve the use of their drug Myfembree for use in the relief of heavy menstrual bleeding associated with uterine fibroids, a chronic and debilitating illness. This marks the first non-invasive treatment of its kind to be offered to women that only needs to be used only once daily. The pill will be jointly licensed by both companies and will be available in late summer 2020. As a result the company's share prices have gone up by 4%.", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_phd", "time_taken_in_seconds": 431145}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_21", "age_group": "31_40", "agreed": true, "close_date_time": "2021-10-25 17:49:53", "close_timestamp": 1637862593272, "created": "25/11/2021 17:49:55", "department": "Visual Cultures", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-25", "gender": "female", "id": "b80fc244-a916-446e-aabd-532e1f47b4a2", "open_date_time": "2021-10-25 17:35:14", "open_timestamp": 1637861714785, "summary": "The European Medical Agency's view on the safety of the Astrazeneca virus remains unchanged after it has been shown that thromboembolic events (blood clots) are no more prevalent in the vaccinated population. Th vaccine will continue to be used to prevent the spread of coronavirus despite concerns of the public. Meanwhile the continuing difficulty of the supply chain for the vaccine continues and the European Union threatens legal action claiming the company is in breach of contractual obligations. ", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_phd", "time_taken_in_seconds": 878487}}}